Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

6.87
+0.06000.88%
Post-market: 6.870.00000.00%18:18 EDT
Volume:22.67K
Turnover:158.32K
Market Cap:42.51M
PE:-2.80
High:7.15
Open:6.82
Low:6.80
Close:6.81
52wk High:13.69
52wk Low:3.76
Shares:6.19M
Float Shares:3.00M
Volume Ratio:0.60
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4500
EPS(LYR):-2.4500
ROE:-196.92%
ROA:-69.33%
PB:0.79
PE(LYR):-2.80

Loading ...

Aligos Therapeutics Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 20

Aligos Therapeutics assumed with a Buy at Jefferies

TIPRANKS
·
Mar 19

Aligos Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 12

Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)

TIPRANKS
·
Mar 05

Aligos Therapeutics Q4 EPS $(1.91) Beats $(2.27) Estimate, Sales $169.000K Miss $800.000K Estimate.

Benzinga
·
Mar 05

Aligos Therapeutics Q4 net loss narrows

Reuters
·
Mar 05

Aligos posts FY 2025 net loss of USD 24.2 million, down 81.6%

Reuters
·
Mar 05

Aligos Therapeutics Q4 Net Income USD -19.881 Million

THOMSON REUTERS
·
Mar 05

Aligos Therapeutics Q4 Income From Operations USD -21.814 Million

THOMSON REUTERS
·
Mar 05

Aligos Therapeutics Q4 Pretax Profit USD -19.851 Million

THOMSON REUTERS
·
Mar 05

Aligos Therapeutics Q4 Operating Expenses USD 21.983 Million

THOMSON REUTERS
·
Mar 05

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Mar 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 05

Top News Today: Stocks Gain as Economic Data Offsets War Fears

Dow Jones
·
Mar 05

Top News Today/Canada: Traders Face Uncertainty Over Iran Conflict, Says BOC's Macklem

Dow Jones
·
Mar 05

Aligos Therapeutics Inc expected to post a loss of $1.85 a share - Earnings Preview

Reuters
·
Mar 03

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026

GlobeNewswire
·
Feb 26

Aligos announces data from two presentations at CROI on pevifoscorvir sodium

TIPRANKS
·
Feb 23

Aligos Therapeutics reports positive Phase 1 pevifoscorvir sodium monotherapy data in chronic HBV infection at CROI 2026

Reuters
·
Feb 23

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

GlobeNewswire
·
Feb 23